Ultragenyx Pharmaceutical Quarterly Cash Flow Statement
NASDAQ: RAREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ultragenyx Pharmaceutical free cash flow
In the quarter ended Jun 30, 2026, Ultragenyx Pharmaceutical generated -$97.0 million of operating cash flow and spent $1.0 million on capital expenditures. That left free cash flow of -$98.0 million, a free-cash-flow margin of -45.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Ultragenyx Pharmaceutical cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -92.00M | -185.00M | -128.56M | -180.41M | -115.00M | -151.00M | -133.20M | -133.52M | -131.60M | -170.68M | -123.55M | -159.65M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 8.00M | 8.00M | 8.79M | 8.21M | 9.00M | 9.00M | 9.54M | 8.76M | 8.86M | 8.85M | 8.21M | 7.19M |
| Stock-Based Compensation | 34.00M | 30.00K | 37.47M | 37.01M | 39.00M | 40.00K | 40.13M | 41.57M | 39.36M | 36.93M | 33.53M | 34.88M |
| Change in Working Capital | -65.00M | 15.00M | -33.68M | 684.00K | -13.00M | 9.00M | -23.29M | 20.01M | -8.97M | -20.48M | -2.50M | -4.68M |
| Operating Cash Flow | -97.00M | -197.00M | -99.83M | -91.17M | -109.00M | -166.00M | -79.31M | -67.00M | -76.96M | -190.73M | -84.10M | -117.87M |
| Capital Expenditures | -1.00M | -1.00M | -938.00K | -1.06M | -3.00M | -1.00M | -163.00K | -1.62M | -2.01M | -3.21M | -1.33M | -3.69M |
| Investing Cash Flow | 44.00M | -49.00M | -72.25M | 117.25M | 71.00M | 120.00M | 102.50M | -275.50M | 60.56M | 94.44M | -107.02M | 64.30M |
| Financing Cash Flow | — | — | 394.19M | -192.00K | 83.84M | 157.00K | 2.94M | 11.17M | 384.94M | -58.00K | 330.47M | 25.23M |
| Net Change in Cash | -49.00M | -247.00M | 221.46M | 25.54M | 50.00M | -45.00M | 24.18M | -330.05M | 367.89M | -97.03M | 139.99M | -29.06M |
| Free Cash Flow | -98.00M | -198.00M | -100.77M | -92.23M | -112.00M | -167.00M | -79.48M | -68.61M | -78.97M | -193.94M | -85.43M | -121.57M |
This table shows 12 quarterly periods of Ultragenyx Pharmaceutical's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RARE's reporting calendar. What is a cash flow statement?